
    
      Adults with a history of migraine with or without aura for ≥ 12 months and who experience ≥ 4
      to < 15 migraine days per month with < 15 headache days per month will be randomized 1:1 to
      placebo or erenumab. Double-blind erenumab or placebo will be administered during the 12-week
      double-blind treatment phase and open-label erenumab will be administered during the 28-week
      open-label treatment phase.
    
  